Merus N.V. (Nasdaq: MRUS) today provided its 2023 outlook.
- As of year-end 2022, more than 150 patients with NRG1 gene fusion positive ("NRG1+") cancer have been treated with zenocutuzumab ("Zeno") monotherapy
- Petosemtamab clinical update planned for first half of 2023
Gainers
Huadi International Group Co., Ltd. (NASDAQ: HUDI) shares jumped 242.8% to close at $105.72 on Thursday. The company announced a strategic plan to enter into the clean energy industry.